Aperio Group LLC Increases Stake in Seattle Genetics, Inc. (NASDAQ:SGEN)

Xavier Trudeau
Août 12, 2017

The stock of Seattle Genetics, Inc. Six analysts have provided estimates for Seattle Genetics' earnings, with estimates ranging from ($0.48) to ($0.34). Seattle Genetics posted earnings per share of ($0.23) during the same quarter last year, which indicates a negative year over year growth rate of 87%.

In the market the company is trading up from yesterday's close of $46.2. The shares were sold at an average price of $65.21, for a total value of $679,683.83.

Shares of Seattle Genetics (SGEN) opened at 46.20 on Thursday.

As of the latest earnings report the EPS was $-1.43 and is estimated to be $-1.70 for the current year with 143,027,000 shares now outstanding. Seattle Genetics had a negative net margin of 47.38% and a negative return on equity of 32.87%. The business had revenue of $108.20 million for the quarter, compared to analyst estimates of $105.92 million. During the same quarter in the previous year, the company posted ($0.15) earnings per share. Seattle Genetics Inc now has $6.61B valuation.

A number of equities analysts have recently commented on SGEN shares. Jefferies Group LLC reissued a "buy" rating and set a $53.00 price objective on shares of Seattle Genetics in a report on Thursday, July 27th.

TRADEMARK VIOLATION NOTICE: "Aperio Group LLC Has $1.64 Million Position in Seattle Genetics, Inc". Cann reiterated a "hold" rating on shares of Seattle Genetics in a report on Monday, June 19th. Oppenheimer Holdings, reiterated a "hold" recommendation on stocks of Seattle Genetics in a note on Saturday, Jun 3rd. Five equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & worldwide copyright and trademark laws. The original version of this story can be read at https://www.chaffeybreeze.com/2017/08/11/aperio-group-llc-increases-stake-in-seattle-genetics-inc-nasdaqsgen.html. (NASDAQ:SGEN) earned "Neutral" rating by Credit Suisse on Monday, December 12. The company has market cap of $1.72 billion. HC Wainwright lifted their price objective on Seattle Genetics from $65.00 to $75.00 and gave the company a "buy" rating in a research report on Friday, April 28th. The shares were sold at an average price of $49.19, for a total transaction of $295,140.00. California Public Employees Retirement System now owns 228,600 shares worth $11,828,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Darren S. Cline sold 6,000 shares of the firm's stock in a transaction dated Monday, August 7th. The company presently has a consensus rating of "Hold" and an average price target of $62.07. The disclosure for this sale can be found here. Gulf International Bank UK Ltd now owns 31,050 shares of the biotechnology company's stock valued at $1,951,000 after buying an additional 250 shares during the period. Insiders own 33.30% of the company's stock.

A number of other large investors have also recently bought and sold shares of SGEN. Dimensional Fund Advisors LP raised its stake in Seattle Genetics by 1.3% in the fourth quarter. Bank of Montreal Can now owns 7,235 shares of the biotechnology company's stock valued at $454,000 after buying an additional 5,332 shares during the period. Moreover, Voya Investment Management Llc has 0.01% invested in Seattle Genetics, Inc. Candriam Luxembourg S.C.A. now owns 99,500 shares of the biotechnology company's stock worth $6,255,000 after buying an additional 27,000 shares during the last quarter. Aperio Group LLC boosted its position in shares of Seattle Genetics by 0.3% in the second quarter. Following the sale, the chief marketing officer now directly owns 125,204 shares of the company's stock, valued at approximately $8,014,308.04. Vanguard Group Incorporated reported 0.02% in Seattle Genetics, Inc. UBS Asset Management Americas Inc. now owns 188,705 shares of the biotechnology company's stock valued at $9,959,000 after buying an additional 104,557 shares during the period. Finally, Atria Investments LLC increased its position in shares of Seattle Genetics by 29.0% in the second quarter. Meeder Asset Management has an ownership of 3,950 stocks of the biotechnology firms shares valued $205,000 after scooping up an extra 3,715 shares through out the quarter.

Want to see what other hedge funds are holding SGEN?

Seattle Genetics, Inc.is a biotechnology firm focused on the development and commercialization of therapies for the treatment of cancer. The Firm is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others.

D'autres rapports CampDesrEcrues

Discuter de cet article